Coherus Biosciences Inc (NASDAQ:CHRS)’s traded shares stood at 1.05 million during the last session, with the company’s beta value hitting 0.83. At the close of trading, the stock’s price was $1.47, to imply an increase of 2.80% or $0.04 in intraday trading. The CHRS share’s 52-week high remains $3.70, putting it -151.7% down since that peak but still an impressive 55.1% since price per share fell to its 52-week low of $0.66. The company has a valuation of $174.10M, with an average of 2.95 million shares in intraday trading volume over the past 10 days and average of 5.19 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Coherus Biosciences Inc (CHRS), translating to a mean rating of 1.33. Of 5 analyst(s) looking at the stock, 0 analyst(s) give CHRS a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 3 recommend it as a Buy.
Coherus Biosciences Inc (NASDAQ:CHRS) trade information
After registering a 2.80% upside in the last session, Coherus Biosciences Inc (CHRS) has traded red over the past five days. The 5-day price performance for the stock is -15.20%, and 33.03% over 30 days. With these gigs, the year-to-date price performance is -56.46%. Short interest in Coherus Biosciences Inc (NASDAQ:CHRS) saw shorts transact 30.72 million shares and set a 8.43 days time to cover.
The extremes give us $6 and $6 for target low and target high price respectively. As such, CHRS has been trading -308.16% off suggested target high and -308.16% from its likely low.
Coherus Biosciences Inc (CHRS) estimates and forecasts
Looking at statistics comparing Coherus Biosciences Inc share performance against respective industry, we note that the company has outperformed competitors. Coherus Biosciences Inc (CHRS) shares are -12.65% down over the last 6 months, with its year-to-date growth rate higher than industry average at 64.65% against 16.70%.
CHRS Dividends
Coherus Biosciences Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Coherus Biosciences Inc (NASDAQ:CHRS)’s Major holders
Coherus Biosciences Inc insiders hold 1.38% of total outstanding shares, with institutional holders owning 70.31% of the shares at 71.30% float percentage. In total, 70.31% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 11.75 million shares (or 10.4236% of shares), all amounting to roughly $20.33 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 10.6 million shares, or about 9.4035% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $18.34 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Coherus Biosciences Inc (CHRS) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 3.43 shares. This is just over 2.98% of the total shares, with a market valuation of $5.05 million. Data from the same date shows that the other fund manager holds a little less at 2.85, or 2.47% of the shares, all valued at about 4.19 million.
